Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer
NCT ID: NCT05507593
Last Updated: 2022-08-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
18 participants
INTERVENTIONAL
2022-09-01
2023-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
NCT07246304
This Study is an Open-lable, Phase I Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
NCT07249879
Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer
NCT00850785
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
NCT06348797
CAR-T Cell Immunotherapy for Advanced Lung Cancer
NCT03330834
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Patients of group A will be received 1x10\^7 DLL3-CAR-NK cells infusion treatment.
DLL3-CAR-NK cells
Patients of Group A will be received 1x10\^7 DLL3-CAR-NK cells infusion treatment，of group B will be received 1x10\^8 DLL3-CAR-NK cells infusion treatment，and of group C will be received 1x10\^9 DLL3-CAR-NK cells infusion treatment.
Group B
Patients of group B will be received 1x10\^8 DLL3-CAR-NK cells infusion treatment.
DLL3-CAR-NK cells
Patients of Group A will be received 1x10\^7 DLL3-CAR-NK cells infusion treatment，of group B will be received 1x10\^8 DLL3-CAR-NK cells infusion treatment，and of group C will be received 1x10\^9 DLL3-CAR-NK cells infusion treatment.
Group C
Patients of group C will be received 1x10\^9 DLL3-CAR-NK cells infusion treatment.
DLL3-CAR-NK cells
Patients of Group A will be received 1x10\^7 DLL3-CAR-NK cells infusion treatment，of group B will be received 1x10\^8 DLL3-CAR-NK cells infusion treatment，and of group C will be received 1x10\^9 DLL3-CAR-NK cells infusion treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DLL3-CAR-NK cells
Patients of Group A will be received 1x10\^7 DLL3-CAR-NK cells infusion treatment，of group B will be received 1x10\^8 DLL3-CAR-NK cells infusion treatment，and of group C will be received 1x10\^9 DLL3-CAR-NK cells infusion treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients voluntarily sign informed consent;
2. The age was 18-75 years old, and the gender was not limited;
3. Patients who meet the following diagnosis and treatment : 1) small cell lung cancer diagnosed by tissue / cytology; 2) extensive small cell lung cancer diagnosed by imaging according to VALG and AJCC-8; 3) disease progression after receiving at least one line treatment, and disease progression within 6 months after the last line treatment;
4. The expected survival time was more than 3 months;
5. There are measurable target lesions on imaging during screening: the maximum diameter is greater than 1.0 cm;
6. The Eastern Cooperative Oncology Group (ECOG) scored 0 or 1 for physical fitness;
7. Sufficient bone marrow reserve at screening, defined as:
* Neutrophil absolute value (ANC) \> 1.5 × 10\^9/L；
* Lymphocyte absolute value (ALC) ≥ 0.3 × 10\^9/L；
* Platelet (PLT) ≥ 100 × 10\^9/L；
* Hemoglobin (HGB) ≥ 100g / L;
8. The screening has appropriate organ function and meets the following criteria:
* Aspartate aminotransferase (AST) ≤ 2.5 times ULN (due to tumor infiltration ≤ 5 times ULN);
* Alanine aminotransferase (ALT) ≤ 2.5 times ULN (due to tumor infiltration ≤ 5 times ULN);
* Total serum bilirubin ≤ 1.5 times ULN (due to tumor infiltration ≤ 3 times ULN);
* Serum creatinine (SCR) ≤ 1.5 times ULN, or creatinine clearance rate ≥ 60ml / min;
* Have the lowest level of lung reserve, defined as ≤ grade 1 dyspnea and oxygen saturation \> 91% in non oxygen breathing state;
* International normalized ratio (INR) ≤ 1.5 times ULN, and activated partial prothrombin time (APTT) ≤ 1.5 times ULN;
9. Blood vessel conditions for collection of mononuclear cells are available during screening;
10. The urine pregnancy test of women of childbearing age is negative. Any male and female patient with fertility must agree to use effective contraceptive methods during the whole study and at least 1 year after the study treatment.
Exclusion Criteria
1. At the time of screening, patients with symptomatic central nervous system (CNS) metastases (asymptomatic CNS metastases, or asymptomatic after local treatment and stable condition for 4 weeks can be enrolled);
2. Those with a history of central nervous system before screening, such as epilepsy, cerebral ischemia / hemorrhage, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, cerebral organic syndrome, mental disease or any autoimmune disease involving the central nervous system;
3. Those who had received immunotherapy, targeted therapy, chemotherapy, or radiotherapy within 4 weeks before screening and were assessed by the investigator as unsuitable for inclusion;
4. Those who stopped systemic hormone therapy for less than 72 hours before cell transfusion; But it is allowed to use a physiological substitute amount of hormone (such as prednisone \< 10mg / D or equivalent);
5. Those who have used any adoptive cell therapy before screening;
6. Those who have received organ / tissue transplantation before screening;
7. Active systemic autoimmune disease is known before screening and is under treatment;
8. Those who meet any of the following conditions during screening:
* positive for hepatitis B surface antigen (HBsAg) and / or hepatitis B e antigen (HBeAg);
* hepatitis B e antibody (HBE AB) and / or hepatitis B core antibody (HBC AB) are positive, and the copy number of HBV-DNA is greater than the lower measurable limit;
* positive for hepatitis C antibody (HCV AB);
* positive anti Treponema pallidum antibody (TP AB);
* HIV antibody test positive;
* the copy number of EBV-DNA and cmv-dna is greater than the lower measurable limit;
9. Those who had undergone major surgery within 4 weeks before screening and were assessed by the investigator as unsuitable for inclusion;
10. Those who had or were suffering from other malignant tumors within 2 years before screening;
11. The heart meets any of the following conditions during screening:
* left ventricular ejection fraction (LVEF) ≤ 50% (echo);
* New York Heart Association (NYHA) class III or IV congestive heart failure;
* hypertension (systolic blood pressure ≥ 140mmHg and / or diastolic blood pressure ≥ 90mmHg) or pulmonary hypertension that has not been controlled by standard treatment;
* have had myocardial infarction or cardiac surgery within 12 months before cell transfusion;
* clinically significant valvular disease.
12. The tumors involved atrium or ventricle during screening;
13. Patients with history of pulmonary interstitial fibrosis or severe COPD;
14. There are clinical emergencies (such as intestinal obstruction or vascular compression) requiring urgent treatment due to tumor body obstruction or compression during screening;
15. Patients with active bleeding during screening;
16. Patients with deep venous thrombosis or pulmonary embolism within 6 months before screening;
17. Those who received live vaccine within 6 weeks before screening;
18. Patients with active infection and need treatment during screening;
19. Participated in other intervention clinical studies within 4 weeks before screening;
20. Poor compliance.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tianjin Medical University Cancer Institute and Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dingzhi Huang, M.D
Role: PRINCIPAL_INVESTIGATOR
Tianjin Medical University Cancer Institute and Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E20220808
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.